The Return of Psilocin: What the First Human Trial Since the 1960s Means for Psychedelic Therapy
By Sasha Stafford | Principal Scientist & Founder | Prodelic Technologies LLC
For decades, the standard in clinical psychedelic research has been relatively uniform: administer a synthetic pill of psilocybin, wait for the patient's liver to metabolize it, and guide them through the resulting hours-long experience. Psilocybin has become the undisputed poster child of the psychedelic renaissance.
However, a groundbreaking new study recently published in the Journal of Psychopharmacology is challenging that standard paradigm. For the first time since the 1960s, researchers have conducted a human trial utilizing psilocin—the actual active compound that causes the psychedelic experience.
The results suggest that skipping the metabolic middleman could lead to a smoother, highly tolerable, and potentially more optimized therapeutic experience.
The Prodrug Problem: Psilocybin vs. Psilocin
To understand why this new trial is so significant, we first have to look at the pharmacology of "magic mushrooms."
When you consume psilocybin—whether in a clinical trial using synthetic COMP360 or by eating a dried Psilocybe cubensis mushroom—your body is ingesting what is known as a prodrug. A prodrug is a biologically inactive compound that must be broken down by the body to become active.
In this case, the liver uses an enzyme to strip a phosphate group from the psilocybin molecule (a process called dephosphorylation). What is left behind is psilocin (C12H17N2O).
Psilocin is the heavy lifter. It is the functional compound that crosses the blood-brain barrier, binds to the 5-HT2A serotonin receptors, and triggers the profound structural brain changes and subjective psychedelic effects we associate with a "trip."
So why have clinical trials historically used psilocybin instead of psilocin?
The answer comes down to stability. Psilocin is notoriously unstable; it degrades and oxidizes rapidly when exposed to air, light, or aqueous solutions. Psilocybin, thanks to that extra phosphate group, is highly stable, making it much easier to synthesize, store, and administer in controlled clinical settings.
But relying on the body to metabolize a prodrug introduces variability. Different people have different metabolic rates. Furthermore, the metabolic process itself is widely believed to contribute to the heavy body load and gastrointestinal distress (nausea) frequently reported by patients taking oral psilocybin.
Inside the New Trial
Led by researchers affiliated with the University of California, San Francisco (UCSF) and the Translational Psychedelic Research (TrPR) Program, this randomized, within-subject, crossover trial aimed to compare the pharmacodynamic profiles and tolerability of three different botanical formulations (developed by Filament Health):
1. Oral Psilocybin (25 mg)
2. Oral Psilocin (17.5 mg)
3. Sublingual Psilocin (2.18, 4.36, or 8 mg)
The trial involved 20 healthy adults who underwent up to four drug administration sessions, all accompanied by standard pre- and post-dose psychotherapy and therapeutic support.
Key Finding #1: Better Tolerability and Less Nausea
The most notable takeaway from the study is that direct oral administration of psilocin resulted in a significantly lower burden of adverse physical side effects compared to oral psilocybin.
For years, psychonauts and recreational users have utilized "Lemon Tekking"—soaking ground mushrooms in acidic lemon juice to pre-convert the psilocybin into psilocin before ingestion—claiming it reduces nausea and speeds up the onset. This clinical trial provides compelling medical data supporting the underlying theory: bypassing the liver's need to aggressively dephosphorylate the compound leads to a physically smoother experience.
Key Finding #2: Equivalent Psychedelic Efficacy
Despite the reduction in negative physical side effects, the researchers noted that oral psilocin produced a temporal and subjective profile deeply similar to oral psilocybin. The emotional breakthroughs, the intensity of the psychedelic experience, and the psychological insights were fundamentally equivalent. Patients didn't lose the profound benefits of the therapy just because the physical "body load" was reduced.
Key Finding #3: The Potential of Sublingual Dosing
The study also explored administering psilocin sublingually (under the tongue). While this delivery method was found to be very well-tolerated, it yielded milder subjective effects at the specific dosages tested, indicating a lower overall drug exposure than swallowing a capsule. However, this opens a fascinating door for future research. A sublingual liquid or dissolving tablet could offer incredibly precise, rapid-onset dosing that could be titrated in real-time by a clinician, much like how intravenous ketamine is currently administered.
What This Means for the Future of Psychedelic Therapy
As the psychedelic industry pushes toward FDA approval for compounds treating depression, PTSD, and addiction, the focus is increasingly shifting toward optimization.
While synthetic psilocybin has proven to be incredibly effective (with companies like COMPASS Pathways advancing through Phase III trials), the side effects—particularly nausea and anxiety during the long onset period—can be distressing for patients already in vulnerable mental states.
By successfully utilizing botanical psilocin, this trial proves that we don't have to settle for the traditional prodrug route. If pharmaceutical developers can overcome the chemical instability of psilocin to create reliable, shelf-stable formulations, direct psilocin administration could become the new gold standard. It promises to bypass unpredictable individual metabolic differences, delivering a faster, physically gentler, and more consistent therapeutic journey.
Science is finally catching up to what mushroom enthusiasts have suspected for years: sometimes, it is better to get straight to the active ingredient.
Reference: Tai ML, Szigeti B, Downey AE, et al. A randomized crossover trial comparing the acute physiological and psychological effects of botanical formulations of oral psilocybin, oral psilocin, and sublingual psilocin. Journal of Psychopharmacology. 2026; doi:10.1177/02698811261478603.
Comments